Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | YES1 | P07947 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.38 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29743248 | 1.00 | ESR2 (0.44) | ESR2ESR1KMT2AKDM4EMEN1 | |
| SCHEMBL3497573 | 0.82 | ESR2 (0.56) | ESR2ESR1KMT2AGUSB | |
| SCHEMBL9800296 | 0.79 | ESR2 (0.49) | ESR2ESR1KMT2AGUSB | |
| SCHEMBL8442229 | 0.78 | SLC6A3 (0.43) | KMT2AKDM4EMEN1CYP3A4MAPT | |
| SCHEMBL21536565 | 0.78 | GSK3B (0.50) | KMT2AMAPK1 | |
| SCHEMBL12572359 | 0.78 | GSK3B (0.50) | KMT2AMAPK1 | |
| SCHEMBL14458014 | 0.77 | ESR2 (0.51) | ESR2ESR1GUSB | |
| SCHEMBL157619 | 0.77 | BRD4 (0.50) | KMT2AKDM4EMEN1MAPT | |
| SCHEMBL6247618 | 0.77 | BRD4 (0.50) | KMT2AKDM4EMEN1MAPT | |
| SCHEMBL9295153 | 0.77 | BRD4 (0.50) | KMT2AKDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | claimed |
| JP-2908031-B2 | — | — | 1999-06-21 | — | — | JP | claimed |
| EP-0792264-A1 | SULFUR-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1997-09-03 | — | — | EP | claimed |
| WO-1996016037-A1 | SULFUR-SUBSTITUTED AZETIDINONE COMPOUNDS USEFUL AS HYPOCHOLESTEROLEMIC AGENTS | SCHERING CORPORATION (US) | 1996-05-30 | — | — | WO | claimed |
| CN-114621299-B | Preparation method of ezetimibe intermediate | 江苏阿尔法药业股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | BAUSCH HEALTH IRELAND LTD (IE) | 2020-04-16 | — | — | US | disclosed |
| US-10597424-B2 | Agonists of guanylate cyclase and their uses | BAUSCH HEALTH IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| CN-105963676-B | Agonists of guanylate cyclase for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstones, obesity and other cardiovascular diseases | 药物协和股份有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-20190263861-A1 | AGONISTS OF GUANYLATE CYCLASE AND THEIR USES | JPMORGAN CHASE BANK, N.A. | 2019-08-29 | — | — | US | disclosed |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | SYNERGY PHARMACEUTICALS INC (US) | 2019-08-29 | — | — | US | disclosed |
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | SYNERGY PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10118946-B2 | Agonists of guanylate cyclase and their uses | SYNERGY PHARMACEUTICALS INC. (US) | 2018-11-06 | — | — | US | disclosed |
| CN-101423515-A | Novel preparation method of Ezetimibe | HUANDA DU (CN) | 2009-05-06 | — | — | CN | disclosed |
| CN-101426496-A | Use of cholesterol lowering agents and/or H3Treatment of non-alcoholic fatty liver disease with receptor antagonists/inverse agonists | SCHERING CORP (US) | 2009-05-06 | — | — | CN | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008137318-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS ASSOCIATED WITH SALT OR FLUID RETENTION | IRONWOOD PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008124505-A2 | SOLUBLE GUANYLATE CYCLASE (SGC) MODULATORS FOR TREATMENT OF LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS,INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| CN-101243072-A | Piperidine derivatives useful as histamine H3 antagonists | SCHERING CORP (US) | 2008-08-13 | — | — | CN | disclosed |
| CN-1805926-A | Process for the preparation of trans-isomers of diphenylazetidinone derivatives | RANBAXY LAB LTD (IN) | 2006-07-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10238712-B2 | Compositions useful for the treatment of gastrointestinal disorders | GUCY1A1, TNF, GUCY1A2 | ESR2 4419/4885ESR1 4831/4885KMT2A 4656/4885 |
| US-20190262420-A1 | COMPOSITIONS USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GUCY1A1, TNF, GUCY1A2 | ESR2 4419/4885ESR1 4831/4885KMT2A 4656/4885 |
| US-20200113968-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR DOWNREGULATION OF PRO-INFLAMMATORY CYTOKINES | GUCY1A1, GUCY1A2, GUCY1B2 | ESR2 2942/4885ESR1 4435/4885KMT2A 4392/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | ESR2 2805/4885ESR1 4780/4885KMT2A 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.